摘要
Over the past decade,there has been notable progress in the systemic treatment of liver cancer.However,despite the emergence of new therapeutic strategies,they have not universally achieved success,with patients afflicted by liver diseases frequently displaying resistance to these treatments(1).Consequently,liver cancer remains a global health challenge,and hepatocellular carcinoma(HCC)stands as the fourth most common cause of cancer-related deaths globally,constituting 80-90%of primary liver cancer cases(2,3).This poses a substantial threat to both the survival and overall well-being of individuals.
基金
supported by the National Natural Science Foundation of China(No.32271470).